Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04396834 · ClinicalTrials.gov registry record · Phase 2
Mechanisms of Lorcaserin for Smoking Cessation
A Phase 2 study, sponsored by The Mind Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04396834 is a Phase 2 study that was terminated before completion, run by The Mind Research Network. The registered enrollment target is 3 participants.
The verdict
NCT04396834, a Phase 2 study, was terminated before completion, sponsored by The Mind Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Identifying new medication options is critical for curbing the health burdens of cigarette smoking. Currently approved smoking cessation medications act on nicotinic receptors, and additional work is needed to identify medications with alternate pharmacological targets. Based on evidence that the serotonin system plays a role in nicotine consumption and relapse, this study will examine whether a selective serotonin medication alters smoking-related behaviors and responses to cigarette smoking under controlled conditions, informing its potential utility for smoking cessation.
Interventions
- DRUG Placebo oral tablet
- DRUG Lorcaserin Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-12-04 |
| Est. Completion | 2020-02-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04396834
The ClinicalTrials.gov registry entry for NCT04396834 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Mind Research Network, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04396834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04396834 about?
NCT04396834 is a clinical study titled "Mechanisms of Lorcaserin for Smoking Cessation". Identifying new medication options is critical for curbing the health burdens of cigarette smoking. Currently approved smoking cessation medications act on nicotinic receptors, and additional work is needed to identify medications with alternate pharmacological targets. Based on evidence that the se...
What is the current status of trial NCT04396834?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-12-04. Estimated completion is 2020-02-26.
What interventions are being tested in trial NCT04396834?
The interventions under investigation include: Placebo oral tablet (DRUG), Lorcaserin Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04396834?
This trial is sponsored by The Mind Research Network, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.